Roche’s Atezolizumab Filing In Sight, With Pivotal Lung Cancer Data In Hand
This article was originally published in The Pink Sheet Daily
Roche’s atezolizumab meets primary endpoint in large Phase II pivotal BIRCH lung cancer study of PD-L1-positive patients, giving hope for an earlier filing of the PD-L1 inhibitor in 2015.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.